Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This
drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The
effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a
protease inhibitor that is already commonly prescribed.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Atazanavir Sulfate Didanosine HIV Protease Inhibitors Nelfinavir Protease Inhibitors Stavudine